Material from the first Phase 2 test has been sent to a leading global fumed silica manufacturer (under LOI) and to an ...

Rocket Pharmaceuticals' shares rallied ahead of the opening bell after the Food and Drug Administration lifted its clinical hold on the biotechnology company's Phase 2 trial of its RP-A501 treatment ...

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) jumped 23% after the U.S. Food and Drug Administration lifted the ...

The MTA board approved an approximately $2 billion tunnel boring contract for the Second Avenue Subway line expansion in ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. Click here to read why SLS stock ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a ...

The MTA has relaunched its Customer Ambassador Program on Monday, Aug 18, continuing the largest customer outreach program in ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Phase 1 of Wyelea consisted of construction of roads and utilities. Phase 2 includes additional roads and infrastructure ...